Preeclampsia Pathophysiology and Clinical Implications

Introduction to Preeclampsia

Preeclampsia is a two-stage disease initiated by abnormal placentation and shallow cytotrophoblast invasion of maternal spiral arteries, leading to placental ischemia that triggers release of anti-angiogenic factors into maternal circulation, causing systemic endothelial dysfunction 1, 2

The primary causative mechanism involves failure of normal spiral artery remodeling during early pregnancy, with the American College of Obstetricians and Gynecologists noting that this failure leads to reduced placental perfusion 3, 4
In normal pregnancy, spiral arteries undergo extensive remodeling, whereas in preeclampsia, this remodeling is severely impaired, resulting in reduced placental perfusion 3, 4, 5
The placenta is the key component in preeclampsia, as evidenced by the disease occurring in hydatidiform mole and the fact that delivery of the placenta is the only definitive cure 4, 1

The ischemic placenta releases pathogenic factors that induce widespread maternal vascular dysfunction, with the European Society of Cardiology stating that these circulating factors cause endothelial dysfunction throughout maternal vasculature 6, 1
Excess soluble Flt-1 (sFlt-1) produced by the stressed placenta is a central mediator, antagonizing vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), creating a deficiency of these pro-angiogenic factors 6

Both maternal and fetal genes contribute to disease risk, with the American Heart Association noting that genetic factors common to both preeclampsia and atherosclerotic disease exist 3, 4, 8, 6
Paternal antigen exposure plays a significant role, with multigravidas pregnant by a new partner having intermediate risk between first pregnancies and subsequent pregnancies with the same partner 3, 9

Preeclampsia is primarily a disease of first pregnancies and extremes of maternal age, with first-time mothers being significantly more susceptible due to new paternal antigen exposure 3, 5, 9
Black women show a preponderance in many nations, and shared risk factors with cardiovascular disease suggest common pathophysiologic mechanisms 3, 7

Delivery of the placenta removes the source of circulating pathogenic factors and remains the only definitive treatment, with the American College of Cardiology recommending this approach 1
Biomarkers (sFlt-1/PlGF ratio) reflect underlying pathophysiology and can help rule out preeclampsia requiring delivery within 7-14 days in suspected cases between 20-34+6 weeks 2
Magnesium sulfate prevents seizures by addressing cerebral autoregulation failure secondary to endothelial dysfunction, as stated by the European Society of Cardiology 1